Europe Immunoglobulin Market Forecast 2022-2030

The Europe immunoglobulin market is predicted to progress with a CAGR of 6.90% across the forecast period of 2022 to 2030. The regional market's growth is fuelled by supportive government initiatives for immunoglobulin and plasma donation, the prevalence of different immunodeficiency diseases, and the growth of the biotechnology industry.

MARKET INSIGHTS

The Europe immunoglobulin market growth evaluation entails the study of the United Kingdom, Italy, Nordic Countries, France, Germany, Spain, and Rest of Europe. The increasing investments by key players as well as industry giants, primarily for vaccine development and research, is one of the major drivers anticipated to strengthen the growth of the immunoglobulin market in France during the forecast years. In this regard, Pfizer announced its plans to include a production facility for an antiviral COVID-19 drug in the country in 2022. It also entails an investment of $594 million in France over the period of the next five years. Similarly, in 2020, AstraZeneca announced an investment of $520 million in the country within the spectrum of manufacturing, research, and development.

On the other hand, in 2019, Spain-based Grifols announced the approval from the United States Food and Drug Administration (FDA) for Xembify®, the company's first 20% subcutaneous immunoglobulin for treating primary immunodeficiencies. The product represents a substantial research and development milestone for Grifols, as well as a critical step for its long-term sustainable growth strategy. Therefore, the abovementioned factors are estimated to propel the Europe immunoglobulin market growth over the forecast years.

COMPETITIVE INSIGHTS

The top companies operating in the market include: LFB Group, Biotest AG, Grifols SA, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 46413

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. GROWTH IN GERIATRIC POPULATION
- 3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
- 3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COST OF THERAPY
- 3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
- 4.6.1. SOURCE
- 4.6.2. APPLICATION
- 4.6.3. EPITOPE
- 4.6.4. VALIDATION

5. MARKET BY PRODUCT

5.1. IGG
5.2. IGA
5.3. IGM
5.4. IGE
5.5. IGD

6. MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN
6.2. SUBCUTANEOUS IMMUNOGLOBULIN
6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA
7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.3. PRIMARY IMMUNODEFICIENCY DISEASES
7.4. MYASTHENIA GRAVIS
7.5. MULTIFOCAL MOTOR NEUROPATHY
7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
7.7. INFLAMMATORY MYOPATHIES
7.8. SPECIFIC ANTIBODY DEFICIENCY
7.9. GUILLAIN-BARRE SYNDROME
7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY
8.2. SPECIALTY PHARMACY
8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER

9.1. HOSPITALS & CLINICS
9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. EUROPE
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. KEY GROWTH ENABLERS
- 10.1.3. KEY CHALLENGES
- 10.1.4. KEY PLAYERS
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED KINGDOM
  - 10.1.5.2. GERMANY
  - 10.1.5.3. FRANCE
  - 10.1.5.4. SPAIN
  - 10.1.5.5. ITALY
  - 10.1.5.6. NORDIC COUNTRIES
  - 10.1.5.7. REST OF EUROPE

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
- 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
- 11.2.1. ADMA BIOLOGICS
- 11.2.2. BIO PRODUCTS LABORATORY
- 11.2.3. BIOTEST AG
- 11.2.4. CHINA BIOLOGIC PRODUCTS INC
- 11.2.5. CSL BEHRING
- 11.2.6. GRIFOLS SA
- 11.2.7. KAMADA LTD
- 11.2.8. KEDRION BIOPHARMA
- 11.2.9. LFB GROUP
- 11.2.10. OCTAPHARMA AG
- 11.2.11. PFIZER INC
- 11.2.12. SANQUIN PLASMA PRODUCTS BV
- 11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- 11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- 11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED